Table 1 Baseline clinical characteristics of patients included in the ORIEN ICI cohort

From: Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors

 

Overall

(N = 1610)

Melanoma

(N = 161)

H&N

(N = 240)

NSCLC

(N = 270)

Others*

(N = 942)

Age at study

Mean

(SD)

61.53 ( ± 12.37)

59.44 ( ± 14.30)

61.19

( ± 10.82)

63.51

( ± 9.58)

61.39

( ± 13.00)

Gender, n (%)

Women

38.70

38.75

17.92

46.67

41.72

Men

61.30

61.25

82.08

53.33

58.28

Ethnicity, n (%)

Hispanic

4.72

8.08

2.92

2.92

5.73

Non-Hispanic

93.42

90.06

96.25

96.25

91.93

Unknown

1.86

1.86

0.83

0.83

2.34

Tumor origin, n (%)

Primary

65.53

35.40

60.80

60.00

73.35

Metastasis

30.12

63.35

31.67

35.56

22.40

Both

4.35

1.24

7.50

4.44

4.25

LDH (serum), U/L

Mean

(SD)

182.5

( ± 127.65)

195.44

( ± 92.87)

194.19

( ± 86.51)

248.20

( ± 181.14)

219.23

( ± 126.52)

Missing %

55.90

45.96

54.58

64.07

55.73

Karnofsky/ECOG PS n(%)

EPS 0/ KPS 100%

12.05

12.42

6.67

13.33

17.95

EPS 1/ KPS 80-90%

10.31

1.86

10.83

18.89

9.13

EPS 2/ KPS 60-70%

2.23

0.62

1.67

3.33

2.33

EPS 3/ KPS 40-50%

0.19

9.32

0.42

0.74

0.00

Unknown

49.01

32.92

56.25

47.41

47.94

Cancer Stage, n (%)

Stage 0

0.19

0.00

0.00

0.00

0.32

Stage I

6.40

3.11

5.00

12.22

5.63

Stage II

8.20

9.32

2.92

14.81

7.54

Stage III

15.84

14.90

7.50

14.33

18.47

Stage IV

17.33

10.56

24.17

18.52

16.45

Unknown

51.99

62.11

60.42

40.00

51.59

Immuno-oncology therapy, n (%)

Ipilimumab

3.11

21.74

0.42

0.00

1.49

Nivolumab

26.02

22.36

27.08

21.11

27.71

Pembrolizumab

49.01

39.75

67.08

58.52

43.31

Avelumab

1.30

0.00

0.00

0.37

2.12

Atezolizumab

6.34

0.621

1.67

7.41

8.17

Cemiplimab

0.56

0.00

0.83

0.00

0.74

Durvalumab

2.55

0.00

0.83

10.37

1.17

Ipilimumab+

Nivolumab

10.99

14.29

2.08

2.22

15.29

Ipilimumab+

Nivolumab/

Pembrolizumab

0.06

0.62

0.00

0.00

0.00

Nivolumab-Relatlimab-rmbw

0.06

0.62

0.00

0.00

0.00

  1. *Others: includes all other cancer types except melanoma, H&N and NSCLC. Note the sum of patients across individual cancer types exceeds N = 1610 because some patients were assigned to more than one cancer type due to multiple tumor or disease classifications in the real-world dataset.
  2. ICI immune checkpoint inhibitor, H&N head and neck, NSCLC non-small cell lung cancer, SD standard deviation.
Back to article page